Arkansas 2023 Regular Session

Arkansas House Bill HB1732

Introduced
3/27/23  
Refer
3/27/23  
Report Pass
3/30/23  
Engrossed
4/3/23  
Refer
4/3/23  
Report Pass
4/5/23  

Caption

To Require Wholesale Distributors Of Controlled Substances To Educate, Communicate, And Provide Due Process For Licensed Professionals Before Limiting Or Terminating Sales Of Controlled Substances; And To Declare An Emergency.

Impact

The legislation's core objective is to regulate the practices surrounding the distribution of controlled substances, thereby enhancing consumer protection and drug safety. By incorporating well-defined processes and timely communication from wholesale distributors, the bill is intended to safeguard licensed professionals, allowing them to address concerns related to drug distribution effectively. Additionally, the bill proposes disciplinary measures for wholesale distributors who fail to comply with its provisions, including significant fines and potential revocation of licensing. This could lead to a more accountable and transparent distribution framework within the state.

Summary

House Bill 1732 mandates wholesale distributors of controlled substances and legend drugs to implement educational and communicative practices that ensure licensed professionals receive a defined procedural due process prior to any actions taken to limit or terminate sales of these substances. The bill aims to clarify the responsibilities and processes for wholesale distributors, particularly in circumstances where they may reduce or entirely stop the distribution of controlled substances to providers or pharmacies. This initiative seeks active collaboration with the Arkansas State Board of Pharmacy to ensure regulatory compliance and oversight related to pharmaceutical distribution practices.

Contention

Notably, the discussions surrounding HB1732 may reflect tensions between regulatory oversight and pharmaceutical business operations. While supporters argue that the bill enhances patient safety and professional accountability, opponents may express concerns over the potential for increased bureaucracy, which could complicate operations for legitimate distributors. The requirement for a complaint-driven process and detailed documentation prior to limiting or terminating distribution might also lead to debates about the balance between compliance and operational efficiency. The emergency clause embedded in the legislation underscores the urgency of these reforms, galvanizing legislative support while potentially sidelining broader stakeholder consultations.

Companion Bills

No companion bills found.

Similar Bills

AR SB502

To Require Wholesale Distributors Of Controlled Substances To Educate, Communicate, And Provide Due Process For Licensed Professionals Before Limiting Or Terminating Sales Of Controlled Substances; And To Declare An Emergency.

AR SB274

To Restrict Wholesale Distributors Of Controlled Substances And Legend Drugs From Limiting Or Terminating Sales Of Controlled Substances To Certain Licensed Professionals; And To Declare An Emergency.

WV SB150

Requiring wholesale drug distributors to report certain information to WV Board of Pharmacy

CA AB458

Importation of prescription drugs.

MN HF1728

Application and renewal fees increased for opiate drug wholesalers, opiate product fee established for opiate drug wholesalers, and sunset for opioid fees eliminated.

MN SF2142

Application and renewal fees increase for opiate drug wholesalers

CA AB602

Pharmacy: nonprescription diabetes test devices.

FL H0283

Storage and Disposal of Prescription Drugs and Sharps